These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33167996)

  • 1. Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital.
    Matsuo K; Nomura H; Uchiyama M; Miyazaki M; Imakyure O
    BMC Health Serv Res; 2020 Nov; 20(1):1017. PubMed ID: 33167996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug Vial Optimization(DVO)for Anti-Cancer Drugs].
    Iwamoto T
    Gan To Kagaku Ryoho; 2017 May; 44(5):353-356. PubMed ID: 28536326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Survey to Compare the Specifications and Stability of Anticancer Drugs in Japan, the United States, Canada, and Australia].
    Matsuyama C; Suzuki S; Gilbar PJ; Yamaguchi M
    Gan To Kagaku Ryoho; 2018 Sep; 45(9):1327-1334. PubMed ID: 30237375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Consideration on Expiration Days Setting for the Introduction of Drug Vial Optimization].
    Hama K; Hirabatake M; Ikesue H; Muroi N; Hashida T
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1139-1143. PubMed ID: 34521792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
    Hess LM; Cui ZL; Li XI; Oton AB; Shortenhaus S; Watson IA
    J Med Econ; 2018 Aug; 21(8):755-761. PubMed ID: 29673274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Centralization impact and cost-saving study in a Moroccan hospital's centralized unit of chemotherapy preparation.
    Adade CA; Benabbes M; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2020 Oct; 26(7):1630-1636. PubMed ID: 32046581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Examination of Actual Medical Material Cost and Cost Reduction Related to Exposure Prevention in the Preparation of Anticancer Drugs].
    Moriya A; Usami E; Hirose T; Takenaka S; Asano H; Okada K; Adachi S; Yoshimura T
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1281-1286. PubMed ID: 31501370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal vial sizes for infliximab injection: a simulation study of Japanese demographic data.
    Nakamura N; Kusumoto M; Yano Y
    Int J Pharm Pract; 2021 Aug; 29(4):344-349. PubMed ID: 33881507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial Optimization for Cost Savings.
    Fukudo M; Ishikawa R; Mishima K; Ono T; Matsumoto S; Tasaki Y
    JCO Oncol Pract; 2020 Oct; 16(10):e1134-e1142. PubMed ID: 32496875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
    Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
    Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a standardised pharmacist check of medical orders prior to preparation of anticancer drugs to reduce drug wastage.
    Yamada H; Kobayashi R; Shimizu S; Yamada Y; Ishida M; Shimoda H; Kato-Hayashi H; Fujii H; Iihara H; Tanaka H; Suzuki A
    Int J Clin Pract; 2020 Apr; 74(4):e13464. PubMed ID: 31830345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.
    Clark L; Castro AP; Fortes AF; Santos F; Clark O; Engel T; Pegoretti B; Teich V; Vianna D; Puty F
    Value Health; 2011; 14(5 Suppl 1):S82-4. PubMed ID: 21839906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lower costs for anticancer drugs by safety margin around calculated dose and by fine-tuning on ampoule strength].
    Mertens S; de Jongh FE
    Ned Tijdschr Geneeskd; 2009; 153():B162. PubMed ID: 19785801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cancer drug wastage on economic evaluations.
    Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW
    Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies.
    Leung CYW; Cheung MC; Charbonneau LF; Prica A; Ng P; Chan KKW
    J Oncol Pract; 2017 Jul; 13(7):e646-e652. PubMed ID: 28605255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world analysis of cancer drug wastage due to oversized vials.
    Liran O; Prus J; Gordon N; Almog V; Gruenewald T; Goldstein DA
    J Am Pharm Assoc (2003); 2018; 58(6):643-646. PubMed ID: 30017368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.